[1]
|
Queremel Milani D A, Davis D D. Pain management medications[M/OL]//Anon. StatPearls [Internet]. Treasure Island: StatPearls Publishing, 2023[2023-11-20]. https://www.ncbi.nlm.nih.gov/books/NBK560692/. |
[2]
|
Yeh C Y, Jao S W, Chen J S, et al. Sebacoyl dinalbuphine ester extended-release injection for long-acting analgesia: a multicenter, randomized, double-blind, and placebo-controlled study in hemorrhoidectomy patients[J]. Clin J Pain, 2017, 33(5): 429-434. doi: 10.1097/AJP.0000000000000417 |
[3]
|
Lumosa Therapeutics. LT1001 extended release analgesic injection [EB/OL]. [2023-11-20]. https://www.lumosa.com.tw/en/pipeline/edit/1. |
[4]
|
Aungst B J, Myers M J, Shefter E, et al. Prodrugs for improved oral nalbuphine bioavailability: inter-species differences in the disposition of nalbuphine and its acetylsalicylate and anthranilate esters[J]. Int J Pharm, 1987, 38(1/3): 199-209. |
[5]
|
Huang J F, Sung K C, Hu O Y P, et al. The effects of electrically assisted methods on transdermal delivery of nalbuph-ine benzoate and sebacoyl dinalbuphine ester from solutions and hydrogels[J]. Int J Pharm, 2005, 297(1/2): 162-171. |
[6]
|
刘欢. 2.5亿元!四川大学华西医院签订2项技术合同联合开发麻醉新药[EB/OL]. (2020-06-15)[2023-11-20]. https://www.wchscu.cn/comprehensive/52075.html.
Liu H. 250 Million yuan! Sichuan University West China Hospital signs two technical contracts to jointly develop new anesthetic drugs[EB/OL]. (2020-06-15)[2023-11-20]. https://www.wchscu.cn/comprehensive/52075.html. |
[7]
|
刘进, 柯博文, 张文胜, 等. 一种季铵盐类化合物及其制备方法与用途: CN201910100568.3[P]. 2019-08-23.
Liu J, Ke B W, Zhang W S, et al. A quaternary ammonium salt compound and its preparation method and application: CN201910100568.3[P]. 2019-08-23. |
[8]
|
柯博文, 刘进, 张文胜, 等. 一种季铵盐类化合物及其制备方法与用途: CN202010071506.7[P]. 2020-05-15.
Ke B W, Liu J, Zhang W S, et al. A quaternary ammonium salt compound and its preparation method and application: CN202010071506.7[P]. 2020-05-15. |
[9]
|
Allen D, Hanumantharao S N, McDonell R, et al. Preclini-cal characterization of the efficacy and safety of biologic N-001 as a novel pain analgesic for post-operative acute pain treatment[J]. Sci Rep, 2023, 13(1): 11778. doi: 10.1038/s41598-023-38618-4 |
[10]
|
Chareancholvanich K, Tantithawornwat S, Ruangsomboon P, et al. Efficacy of epinephrine in local infiltration analgesia on pain relief and opioid consumption following total knee arthroplasty: a randomized controlled trial[J]. Acta Orthop, 2023, 94: 97-101. doi: 10.2340/17453674.2023.8482 |
[11]
|
Li F Z, Guo L, Huang Z J, et al. Effects of dexmedeto-midine as an adjuvant to ropivacaine or ropivacaine alone on duration of postoperative analgesia: a systematic review and meta-analysis of randomized controlled trials[J]. PLoS One, 2023, 18(10): e0287296. doi: 10.1371/journal.pone.0287296 |
[12]
|
Wei X M, Liu Z, Lv L C, et al. Comparison of dexmedetomidine and dexamethasone as adjuvants to the ultrasound-guided interscalene nerve block in arthroscopic shoulder surgery: a systematic review and Bayesian network meta-analysis of randomized controlled trials[J]. Front Med (Lausanne), 2023, 10: 1159216. |
[13]
|
Bailard N S, Ortiz J, Flores R A. Additives to local anesthetics for peripheral nerve blocks: evidence, limitations, and recommendations[J]. Am J Health Syst Pharm, 2014, 71(5): 373-385. doi: 10.2146/ajhp130336 |
[14]
|
Racle J P, Jourdren L, Benkhadra A, et al. Effect of adding sodium bicarbonate to bupivacaine for spinal anesthesia in elderly patients[J]. Anesth Analg, 1988, 67(6): 570-573. |
[15]
|
Balocco A L, Van Zundert P G E, Gan S S, et al. Extended release bupivacaine formulations for postoperative analgesia: an update[J]. Curr Opin Anaesthesiol, 2018, 31(5): 636-642. doi: 10.1097/ACO.0000000000000648 |
[16]
|
Finneran J J 4th, Ilfeld B M. Continuous peripheral nerve blocks for analgesia following painful ambulatory surgery: a review with focus on recent developments in infusion technology[J]. Curr Opin Anaesthesiol, 2023, 36(5): 525-532. doi: 10.1097/ACO.0000000000001284 |
[17]
|
Nicolotti D, Iotti E, Fanelli G, et al. Perineural catheter infection: a systematic review of the literature[J]. J Clin Anesth, 2016, 35: 123-128. doi: 10.1016/j.jclinane.2016.07.025 |
[18]
|
He Y M, Qin L N, Huang Y G, et al. Advances of nano-structured extended-release local anesthetics[J]. Nanoscale Res Lett, 2020, 15(1): 13. doi: 10.1186/s11671-019-3241-2 |
[19]
|
Lin W F, Goldberg R, Klein J. Poly-phosphocholination of liposomes leads to highly-extended retention time in mice joints[J]. J Mater Chem B, 2022, 10(15): 2820-2827. doi: 10.1039/D1TB02346B |
[20]
|
Malige A, Pellegrino A N, Kunkle K, et al. Liposomal bupivacaine in adductor canal blocks before total knee arthroplasty leads to improved postoperative outcomes: a randomized controlled trial[J]. J Arthroplasty, 2022, 37(8): 1549-1556. doi: 10.1016/j.arth.2022.03.073 |
[21]
|
Ilfeld B M, Eisenach J C, Gabriel R A. Clinical effective-ness of liposomal bupivacaine administered by infiltration or peripheral nerve block to treat postoperative pain[J]. Anesthesiology, 2021, 134(2): 283-344. doi: 10.1097/ALN.0000000000003630 |
[22]
|
Nguyen A, Grape S, Gobbetti M, et al. The postoperative analgesic efficacy of liposomal bupivacaine versus long-acting local anaesthetics for peripheral nerve and field blocks: a systematic review and meta-analysis, with trial sequential analysis[J]. Eur J Anaesthesiol, 2023, 40(9): 624-635. doi: 10.1097/EJA.0000000000001833 |
[23]
|
中国科学院过程工程研究所. 国内首个长效镇痛类均一粒径微球缓释制剂获临床批件[EB/OL]. (2022-01-12)[2023-11-20]. https://ipe.cas.cn/xwdt_/kyjz/202201/t20220112_6339476.html.
Institute of Process Engineering, Chinese Academy of Sciences. The first domestically produced long-acting analgesic uniformly sized microsphere sustained-release formulation has received clinical approval[EB/OL]. (2022-01-12)[2023-11-20]. https://ipe.cas.cn/xwdt_/kyjz/202201/t20220112_6339476.html. |
[24]
|
绿叶制药集团. 国内首个罗哌卡因多囊脂质体创新制剂即将进入临床, 有望实现长效缓释镇痛、提升用药安全性[EB/OL]. (2021-03-08)[2023-11-20]. https://www.luye.cn/lvye/view.php?id=1314.
Luye Pharma. The first domestic innovative formulation of ropivacaine liposomes is about to enter clinical practice, which is expected to achieve long-term sustained release analgesia and improve medication safety[EB/OL]. (2021-03-08)[2023-11-20]. https://www.luye.cn/lvye/view.php?id=1314. |
[25]
|
Wang T, Hurwitz O, Shimada S G, et al. Anti-nociceptive effects of bupivacaine-encapsulated PLGA nanoparticles applied to the compressed dorsal root ganglion in mice[J]. Neurosci Lett, 2018, 668: 154-158. doi: 10.1016/j.neulet.2018.01.031 |
[26]
|
He Y M, Qin L N, Fang Y H, et al. Electrospun PLGA nanomembrane: a novel formulation of extended-release bupivacaine delivery reducing postoperative pain[J]. Mater Des, 2020, 193: 108768. doi: 10.1016/j.matdes.2020.108768 |
[27]
|
Pacira Pharmaceuticals. EXPAREL|Non-opioid analgesic pain management[EB/OL]. [2023-11-20]. https://www.exparel.com/. |
[28]
|
Zhang Y J, Shi K, Yang X, et al. Sustained release of levobupivacaine from temperature-sensitive injectable hydrogel for long-term local anesthesia in postoperative pain management[J]. Biomaterials, 2023, 299: 122129. doi: 10.1016/j.biomaterials.2023.122129 |
[29]
|
Ji T J, Li Y, Deng X R, et al. Delivery of local anaesthetics by a self-assembled supramolecular system mimicking their interactions with a sodium channel[J]. Nat Biomed Eng, 2021, 5(9): 1099-1109. doi: 10.1038/s41551-021-00793-y |
[30]
|
Innocoll Biotherapeutics. FDA approves XARACOLL® (bupivacaine HCl) implant, a non-opioid, drug-device treatment option for acute postsurgical pain relief for up to 24 hours following open inguinal hernia repair in adults[EB/OL]. [2023-11-20]. https://www.innocol..com/news-and-media/2020/08/fda-approves-xaracoll-bupivacaine-hcl-impl-ant-a-non-opioid-drug-device-treatment-option-for-acute-post-surgical-pain-relief-for-up-to-24-hours-following-open-inguinal-hernia-repair-in-adults/. |
[31]
|
Ekelund A, Peredistijs A, Grohs J, et al. SABER-bupivacaine reduces postoperative pain and opioid consumption after arthroscopic subacromial decompression: a randomized, placebo-controlled trial[J]. J Am Acad Orthop Surg Glob Res Rev, 2022, 6(5): e21.00287. |
[32]
|
Innocoll Pharmaceuticals Limited. How it works-SABER technology|POSIMIR® [EB/OL]. [2023-11-20]. https://posimir.com/technology/. |
[33]
|
Guo W, Cao D L G, Rao W H, et al. Achieving long-acting local analgesia using an intelligent hydrogel encapsulated with drug and pH regulator[J]. ACS Appl Mater Interfaces, 2023, 15(36): 42113-42129. doi: 10.1021/acsami.3c03149 |
[34]
|
Zhang W J, Xu W G, Ning C, et al. Long-acting hydrogel/microsphere composite sequentially releases dexmedetomid-ine and bupivacaine for prolonged synergistic analgesia[J]. Biomaterials, 2018, 181: 378-391. doi: 10.1016/j.biomaterials.2018.07.051 |
[35]
|
He Y M, Sun F R, Li M H, et al. A gel/fiber composite formulation achieves sequential delivery based on multimodal analgesia reducing chronic pain[J]. Mater Des, 2023, 225: 111541. doi: 10.1016/j.matdes.2022.111541 |
[36]
|
Li M H, He Y M, Liu Z R, et al. Construction of meloxicam and bupivacaine co-delivery nanosystem based on the pathophysiological environment of surgical injuries for enhanced postoperative analgesia[J]. Nano Res, 2023, 16(12): 13301-13308. doi: 10.1007/s12274-023-6074-3 |
[37]
|
Heller J, Barr J. Biochronomer technology[J]. Expert Opin Drug Deliv, 2005, 2(1): 169-183. doi: 10.1517/17425247.2.1.169 |
[38]
|
Blair H A. Bupivacaine/meloxicam prolonged release: a review in postoperative pain[J]. Drugs, 2021, 81(10): 1203-1211. doi: 10.1007/s40265-021-01551-9 |
[39]
|
Heron Therapeutics. ZYNRELEF® [EB/OL]. [2023-11-20]. https://www.herontx.com/product-portfolio/zynrelef/. |